Rituxan observational study old CLL

[Guest guest]

This is a large study using the SEER database.

The study goal was to characterize older CLL patients and to

evaluate outcomes in those patients who initiated infused

therapy, which included or did not include Rituxan.

Quote:

" In conclusion, our findings suggest that initial treatment

with rituximab was associated with improved survival in a

heterogeneous group of more than 2000 older CLL patients,

particularly in patients using fludarabine-based

chemotherapy.

Although rituximab was associated with an increase in the

use of cytopenia interventions, it was not associated with

an increase in overall hospitalizations. Further clinical

studies may be warranted in an older patient population to

confirm these findings, particularly those related to

rituximab monotherapy. "

End quote

FULL PDF-

http://bloodjournal.hematologylibrary.org/content/117/13/3505.full.pdf

or

http://tinyurl.com/3jtosmv